GlassScriptPhysician profile
Andrew L Macina
NPI 1265427082
$8,893.35
in general payments reported to CMS, 2019-2025
23 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,154 · 2020: $991 · 2021: $643 · 2022: $855 · 2023: $1,337 · 2024: $1,617 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,250.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,261.36 | 2019-2025 | |
| Pfizer INC. | $1,117.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $850.60 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.48 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $673.69 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $662.12 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $625.83 | 2019-2024 | Farxiga |
| Chiesi USA, INC. | $409.43 | 2019-2024 | Kengreal, Cleviprex |
| Kiniksa Pharmaceuticals International, Plc | $378.31 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.07 | 2019-2023 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $320.14 | 2021-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $190.01 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $184.24 | 2022-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $177.71 | 2023-2024 | Onpattro |
| Abbott Laboratories | $151.45 | 2020-2024 | Mitraclip, Perclose Prostyle |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $146.76 | 2019 | |
| Astellas Pharma US INC | $142.39 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $121.13 | 2019 | |
| Gilead Sciences, INC. | $117.99 | 2019 | |
| Esperion Therapeutics, INC. | $98.30 | 2020-2022 | |
| Abiomed | $97.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.41 | 2019 | |
| Portola Pharmaceuticals, LLC | $27.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Macina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.